WO2001002005A3 - Induction de la tolerance immunitaire - Google Patents

Induction de la tolerance immunitaire Download PDF

Info

Publication number
WO2001002005A3
WO2001002005A3 PCT/GB2000/002546 GB0002546W WO0102005A3 WO 2001002005 A3 WO2001002005 A3 WO 2001002005A3 GB 0002546 W GB0002546 W GB 0002546W WO 0102005 A3 WO0102005 A3 WO 0102005A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
cells
tolerance
induction
cell
Prior art date
Application number
PCT/GB2000/002546
Other languages
English (en)
Other versions
WO2001002005A2 (fr
Inventor
David John Roberts
Britta Christina Urban
Original Assignee
Isis Innovation
David John Roberts
Britta Christina Urban
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, David John Roberts, Britta Christina Urban filed Critical Isis Innovation
Priority to AU56952/00A priority Critical patent/AU5695200A/en
Priority to EP00942249A priority patent/EP1196543A2/fr
Priority to CA002378477A priority patent/CA2378477A1/fr
Publication of WO2001002005A2 publication Critical patent/WO2001002005A2/fr
Publication of WO2001002005A3 publication Critical patent/WO2001002005A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464414—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

On décrit des procédés et des compositions qui permettent d'induire une tolérance immunitaire dans des cellules de présentation d'antigène de mammifère telles que des cellules dendritiques, des macrophages, des monocytes et des lymphocytes B. Ces procédés et ces compostions impliquent l'utilisation d'agonistes des récepteurs de surface cellulaire CD36, CD51, des récepteurs de thrombospondine et/ou des Bêta intégrines qui, une fois exposés à une cellule présentant l'antigène telle qu'une cellule dendritique sont capables d'inhiber la maturation dans ces derniers. Par conséquent l'aptitude des cellules à favoriser la réponse immunitaire est inhibée. La tolérance à un antigène spécifique peut être induite dans des cellules présentant l'antigène au moyen de l'exposition à un ou plusieurs agonistes précités et à l'antigène. Des préparations de cellules peuvent ainsi être préparées pour être administrées à des humains chez qui la tolérance à un ou plusieurs antigènes spécifiques doit être induite, par exemple en cas de transplants d'allogreffes ou de xénogreffes ou en cas de maladie auto-immune.
PCT/GB2000/002546 1999-06-30 2000-06-30 Induction de la tolerance immunitaire WO2001002005A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU56952/00A AU5695200A (en) 1999-06-30 2000-06-30 Induction of immune tolerance
EP00942249A EP1196543A2 (fr) 1999-06-30 2000-06-30 Traitement de cellules dendritiques pour l'induction de la tolerance immunitaire
CA002378477A CA2378477A1 (fr) 1999-06-30 2000-06-30 Induction de la tolerance immunitaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915311.6A GB9915311D0 (en) 1999-06-30 1999-06-30 Modulation of dendritic cell maturation
GB9915311.6 1999-06-30

Publications (2)

Publication Number Publication Date
WO2001002005A2 WO2001002005A2 (fr) 2001-01-11
WO2001002005A3 true WO2001002005A3 (fr) 2001-07-05

Family

ID=10856356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002546 WO2001002005A2 (fr) 1999-06-30 2000-06-30 Induction de la tolerance immunitaire

Country Status (5)

Country Link
EP (1) EP1196543A2 (fr)
AU (1) AU5695200A (fr)
CA (1) CA2378477A1 (fr)
GB (1) GB9915311D0 (fr)
WO (1) WO2001002005A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135550A1 (fr) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Agents de contraste ciblant un biomarqueur et leur utilisation en imagerie par résonance magnétique pour détection de plaque d'athérosclérose

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015609A1 (fr) * 1989-06-15 1990-12-27 Med-Tal, Inc. Prophylaxie et traitement d'infections microbiennes avec des phosphoglycerides
WO1993006848A1 (fr) * 1991-10-03 1993-04-15 The Center For Blood Research IMMUNOADHESINES DE CD36 ET LEUR UTILISATION POUR TUER DE MANIERE SELECTIVE LES ERYTHROCYTES INFECTES PAR $i(PLASMODIUM FALCIPARUM)
WO1995005191A1 (fr) * 1993-08-13 1995-02-23 Uab Research Foundation Procedes et compositions utiles pour stimuler et inhiber l'activite du facteur de croissance transformant de type beta
WO1996033736A1 (fr) * 1995-04-27 1996-10-31 Affymax Technologies N.V. Peptides du paludisme et vaccins associes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015609A1 (fr) * 1989-06-15 1990-12-27 Med-Tal, Inc. Prophylaxie et traitement d'infections microbiennes avec des phosphoglycerides
WO1993006848A1 (fr) * 1991-10-03 1993-04-15 The Center For Blood Research IMMUNOADHESINES DE CD36 ET LEUR UTILISATION POUR TUER DE MANIERE SELECTIVE LES ERYTHROCYTES INFECTES PAR $i(PLASMODIUM FALCIPARUM)
WO1995005191A1 (fr) * 1993-08-13 1995-02-23 Uab Research Foundation Procedes et compositions utiles pour stimuler et inhiber l'activite du facteur de croissance transformant de type beta
WO1996033736A1 (fr) * 1995-04-27 1996-10-31 Affymax Technologies N.V. Peptides du paludisme et vaccins associes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALBERT M L ET AL: "Immature dendritic cells phagocytose apoptotic cells via alpha V beta 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 7, 5 October 1998 (1998-10-05), pages 1359 - 1368, XP000906793 *
MCCORMICK C J ET AL: "Intercellular adhesion molecule-1 and CD36 synergize to mediate adherence of Plasmodium falciparum-infected erythrocytes to cultured human microvascular endothelial cells.", JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 10, 15 November 1997 (1997-11-15), pages 2521 - 2529, XP000971964 *
URBAN B C ET AL: "Modulation of dendritic cell maturation and function.", TISSUE ANTIGENS, vol. 55, no. Supplement 1, 2000, 7th Workshop and Conference on Human Leucocyte Differentiation Antigens; Harrogate, England; 20-24 June 2000, pages 61, XP000971966 *
URBAN B C ET AL: "Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells.", NATURE, vol. 400, no. 6739, 1 July 1999 (1999-07-01), pages 73 - 77, XP002156922 *

Also Published As

Publication number Publication date
EP1196543A2 (fr) 2002-04-17
CA2378477A1 (fr) 2001-01-11
WO2001002005A2 (fr) 2001-01-11
GB9915311D0 (en) 1999-09-01
AU5695200A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
CA2172507A1 (fr) Procedes et compositions de microencapsulation d'adjuvants
KR970706013A (ko) 암에 대해 면역학적 치료활성이 있는 스트레스 단백질-펩티드 복합체 (immunotherapeutic stress protein-peptide complexes against cancer)
Weisberger et al. Suppression of antibody synthesis and prolongation of homograft survival by chloramphenicol
WO1998033527A3 (fr) Immunotherapie anticancer a base de cellules semi-allogeniques
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
AU6253898A (en) Use of microparticles combined with submicron oil-in-water emulsions
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
AU3518397A (en) Methods for inducing antigen-specific T cell tolerance
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
Braakman et al. Are MHC class II-restricted cytotoxic T lymphocytes important?
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
EP0859625A4 (fr) Composition et procedes permettant d'accentuer les reponses immunitaires dues aux cellules presentatrices d'antigene
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
AU8067198A (en) Compositions for delivery of biological agents and methods for the preparation thereof
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
WO2002034287A3 (fr) Nouvelles formulations de vaccin therapeutique
WO2001002005A3 (fr) Induction de la tolerance immunitaire
Beraud et al. Suppressor cells in Lewis rats with experimental allergic encephalomyelitis: prevention of the disease and inhibition of lymphocyte proliferation by the suppressor cells or their products
WO1998039027A3 (fr) Antigenes de sialyl lewis uilises comme cibles en immunotherapie
CA2491524A1 (fr) Vaccin contre la septicemie rickettsienne des salmonides
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same
Gray et al. Immunosuppressive effects of adamantoyl cytarabine—I: Inhibition of hemagglutinin formation0 and graft versus host reactions in mice
WO1999047102A3 (fr) Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2378477

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 56952/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000942249

Country of ref document: EP

ENP Entry into the national phase

Ref country code: AT

Ref document number: 2000 9159

Date of ref document: 20010322

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 20009159

Country of ref document: AT

WWP Wipo information: published in national office

Ref document number: 2000942249

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000942249

Country of ref document: EP